[SCHEDULE 13G/A] Inozyme Pharma, Inc. SEC Filing
Adage Capital Management, L.P., together with principals Robert Atchinson and Phillip Gross, filed an Amendment to Schedule 13G for Inozyme Pharma, Inc. (INZY). The filing reports 0.00 shares beneficially owned and 0% of the class, with sole and shared voting and dispositive power all shown as 0. The issuer's principal executive office is listed at 321 Summer Street, Suite 400, Boston, MA, and the reporting persons' business address is 200 Clarendon Street, 52nd Floor, Boston, MA. Signatures dated 08/12/2025 certify the information and state the securities were not acquired to influence control.
Adage Capital Management, L.P., insieme ai principali responsabili Robert Atchinson e Phillip Gross, ha depositato un emendamento al Schedule 13G per Inozyme Pharma, Inc. (INZY). La comunicazione riporta 0.00 azioni possedute a titolo beneficiario e 0% della classe; i poteri di voto e di disposizione, sia in forma esclusiva che condivisa, sono indicati tutti come 0. La sede principale dell'emittente 猫 riportata in 321 Summer Street, Suite 400, Boston, MA, mentre l'indirizzo professionale dei soggetti che presentano la comunicazione 猫 200 Clarendon Street, 52nd Floor, Boston, MA. Le firme, datate 08/12/2025, certificano le informazioni e dichiarano che i titoli non sono stati acquisiti per influenzare il controllo.
Adage Capital Management, L.P., junto con los principales responsables Robert Atchinson y Phillip Gross, present贸 una enmienda al Schedule 13G para Inozyme Pharma, Inc. (INZY). La presentaci贸n indica 0.00 acciones en propiedad beneficiaria y 0% de la clase; los poderes exclusivos y compartidos de voto y disposici贸n aparecen todos como 0. La oficina principal del emisor figura en 321 Summer Street, Suite 400, Boston, MA, y la direcci贸n comercial de las personas informantes es 200 Clarendon Street, 52nd Floor, Boston, MA. Las firmas, fechadas 08/12/2025, certifican la informaci贸n y declaran que los valores no fueron adquiridos para influir en el control.
Adage Capital Management, L.P.電� 毂呾瀯鞛� Robert Atchinson 氚� Phillip Gross鞕� 頃粯 Inozyme Pharma, Inc. (INZY)鞐� 雽�頃� Schedule 13G 靾橃爼靹滊ゼ 鞝滌稖頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 0.00欤�鞚� 鞁れ唽鞙�(beneficially owned)鞕� 頃措嫻 欤检嫕鞚� 0%臧� 氤搓碃霅橃柎 鞛堨溂氅�, 雼弲 氚� 瓿惦彊鞚� 鞚橁舶甓岅臣 觳橂秳甓岇潃 氇憪 0搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氚滍枆須岇偓鞚� 氤胳偓 欤检唽電� 321 Summer Street, Suite 400, Boston, MA搿�, 氤搓碃鞛愲摛鞚� 鞐呺 欤检唽電� 200 Clarendon Street, 52nd Floor, Boston, MA搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 08/12/2025鞛� 靹滊獏鞚� 鞝曤炒鞚� 鞝曧檿靹膘潉 頇曥澑頃橂┌ 頃措嫻 歃濌秾鞚� 歆�氚瓣秾鞚� 鞏魂赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 氇呾嫓頃╇媹雼�.
Adage Capital Management, L.P., conjointement avec les dirigeants Robert Atchinson et Phillip Gross, a d茅pos茅 un amendement au Schedule 13G pour Inozyme Pharma, Inc. (INZY). Le d茅p么t indique 0.00 actions d茅tenues 脿 titre b茅n茅ficiaire et 0% de la cat茅gorie ; les pouvoirs de vote et de disposition, tant exclusifs que partag茅s, sont tous indiqu茅s comme 0. Le si猫ge social de l'茅metteur est mentionn茅 au 321 Summer Street, Suite 400, Boston, MA, et l'adresse professionnelle des personnes d茅clarante est 200 Clarendon Street, 52nd Floor, Boston, MA. Les signatures dat茅es du 08/12/2025 certifient les informations et d茅clarent que les titres n'ont pas 茅t茅 acquis dans le but d'influencer le contr么le.
Adage Capital Management, L.P. hat gemeinsam mit den Verantwortlichen Robert Atchinson und Phillip Gross eine 脛nderung zum Schedule 13G f眉r Inozyme Pharma, Inc. (INZY) eingereicht. Die Einreichung meldet 0.00 Aktien, die wirtschaftlich gehalten werden, und 0% der Klasse; die alleinigen und gemeinsamen Stimm- und Verf眉gungsrechte sind alle mit 0 angegeben. Der Hauptsitz des Emittenten ist mit 321 Summer Street, Suite 400, Boston, MA angegeben, und die Gesch盲ftsadresse der meldenden Personen lautet 200 Clarendon Street, 52nd Floor, Boston, MA. Unterschriften vom 08/12/2025 best盲tigen die Angaben und erkl盲ren, dass die Wertpapiere nicht zum Zwecke der Einflussnahme auf die Kontrolle erworben wurden.
- None.
- None.
Insights
TL;DR: Adage's 13G/A shows no ownership of INZY, so there is no material ownership stake or voting influence reported.
The filing explicitly reports 0.00 shares and 0% beneficial ownership for Adage Capital Management, L.P., and the named individuals. That means the reporting persons do not hold a reported economic or voting position in Inozyme Pharma under this filing. For investors, this disclosure is informational and does not reflect an active stake or change in ownership that would affect company control or capital structure.
TL;DR: Formal Schedule 13G/A filing with certifications; no indication of control intent or group ownership.
The statement includes the standard certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control. Item responses show ownership of 5 percent or less and Items 6鈥�9 are marked Not Applicable. Signatures from Adage and the two individuals dated 08/12/2025 complete the filing. Procedurally sound but not material to governance given the reported 0% ownership.
Adage Capital Management, L.P., insieme ai principali responsabili Robert Atchinson e Phillip Gross, ha depositato un emendamento al Schedule 13G per Inozyme Pharma, Inc. (INZY). La comunicazione riporta 0.00 azioni possedute a titolo beneficiario e 0% della classe; i poteri di voto e di disposizione, sia in forma esclusiva che condivisa, sono indicati tutti come 0. La sede principale dell'emittente 猫 riportata in 321 Summer Street, Suite 400, Boston, MA, mentre l'indirizzo professionale dei soggetti che presentano la comunicazione 猫 200 Clarendon Street, 52nd Floor, Boston, MA. Le firme, datate 08/12/2025, certificano le informazioni e dichiarano che i titoli non sono stati acquisiti per influenzare il controllo.
Adage Capital Management, L.P., junto con los principales responsables Robert Atchinson y Phillip Gross, present贸 una enmienda al Schedule 13G para Inozyme Pharma, Inc. (INZY). La presentaci贸n indica 0.00 acciones en propiedad beneficiaria y 0% de la clase; los poderes exclusivos y compartidos de voto y disposici贸n aparecen todos como 0. La oficina principal del emisor figura en 321 Summer Street, Suite 400, Boston, MA, y la direcci贸n comercial de las personas informantes es 200 Clarendon Street, 52nd Floor, Boston, MA. Las firmas, fechadas 08/12/2025, certifican la informaci贸n y declaran que los valores no fueron adquiridos para influir en el control.
Adage Capital Management, L.P.電� 毂呾瀯鞛� Robert Atchinson 氚� Phillip Gross鞕� 頃粯 Inozyme Pharma, Inc. (INZY)鞐� 雽�頃� Schedule 13G 靾橃爼靹滊ゼ 鞝滌稖頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 0.00欤�鞚� 鞁れ唽鞙�(beneficially owned)鞕� 頃措嫻 欤检嫕鞚� 0%臧� 氤搓碃霅橃柎 鞛堨溂氅�, 雼弲 氚� 瓿惦彊鞚� 鞚橁舶甓岅臣 觳橂秳甓岇潃 氇憪 0搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氚滍枆須岇偓鞚� 氤胳偓 欤检唽電� 321 Summer Street, Suite 400, Boston, MA搿�, 氤搓碃鞛愲摛鞚� 鞐呺 欤检唽電� 200 Clarendon Street, 52nd Floor, Boston, MA搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 08/12/2025鞛� 靹滊獏鞚� 鞝曤炒鞚� 鞝曧檿靹膘潉 頇曥澑頃橂┌ 頃措嫻 歃濌秾鞚� 歆�氚瓣秾鞚� 鞏魂赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 氇呾嫓頃╇媹雼�.
Adage Capital Management, L.P., conjointement avec les dirigeants Robert Atchinson et Phillip Gross, a d茅pos茅 un amendement au Schedule 13G pour Inozyme Pharma, Inc. (INZY). Le d茅p么t indique 0.00 actions d茅tenues 脿 titre b茅n茅ficiaire et 0% de la cat茅gorie ; les pouvoirs de vote et de disposition, tant exclusifs que partag茅s, sont tous indiqu茅s comme 0. Le si猫ge social de l'茅metteur est mentionn茅 au 321 Summer Street, Suite 400, Boston, MA, et l'adresse professionnelle des personnes d茅clarante est 200 Clarendon Street, 52nd Floor, Boston, MA. Les signatures dat茅es du 08/12/2025 certifient les informations et d茅clarent que les titres n'ont pas 茅t茅 acquis dans le but d'influencer le contr么le.
Adage Capital Management, L.P. hat gemeinsam mit den Verantwortlichen Robert Atchinson und Phillip Gross eine 脛nderung zum Schedule 13G f眉r Inozyme Pharma, Inc. (INZY) eingereicht. Die Einreichung meldet 0.00 Aktien, die wirtschaftlich gehalten werden, und 0% der Klasse; die alleinigen und gemeinsamen Stimm- und Verf眉gungsrechte sind alle mit 0 angegeben. Der Hauptsitz des Emittenten ist mit 321 Summer Street, Suite 400, Boston, MA angegeben, und die Gesch盲ftsadresse der meldenden Personen lautet 200 Clarendon Street, 52nd Floor, Boston, MA. Unterschriften vom 08/12/2025 best盲tigen die Angaben und erkl盲ren, dass die Wertpapiere nicht zum Zwecke der Einflussnahme auf die Kontrolle erworben wurden.
FAQ
What does the Schedule 13G/A filed for INZY state about ownership?
Who filed the Schedule 13G/A for Inozyme Pharma (INZY)?
What are the relevant dates in the INZY 13G/A filing?
What addresses are listed in the INZY Schedule 13G/A?
Does the filing indicate any intent to influence control of Inozyme (INZY)?
